Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Falgreen

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Briefings in Bioinformatics|April 23, 2013
Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/BioconductorMaria Rodrigo-Domingo, Rasmus Waagepetersen, Julie Støve Bødker, et al.
BMC Bioinformatics|April 13, 2016
Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive ratesAnders E Bilgrau, Steffen Falgreen, Anders Petersen, et al.
Plos One|May 12, 2011
Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell linesMartin Boegsted, Johanne M Holst, Kirsten Fogd, et al.
BMC Bioinformatics|June 7, 2014
Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibitionSteffen Falgreen, Maria Bach Laursen, Julie Støve Bødker, et al.
Diabetes Care|May 12, 2019
Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 TrialBruce W Bode, Violeta Iotova, Margarita Kovarenko, et al.
Oncotarget|January 27, 2015
MicroRNAs in B-cells: from normal differentiation to treatment of malignanciesSara Correia Marques, Maria Bach Laursen, Julie Støve Bødker, et al.
Danish Medical Journal|March 3, 2016
Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic reviewMette Østergaard Poulsen, Laura Krogh Jørgensen, Suzette Sørensen, et al.
Experimental Hematology|July 30, 2014
Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myelomaMaria Bach Laursen, Steffen Falgreen, Julie Støve Bødker, et al.
Cytometry. Part B, Clinical Cytometry|February 14, 2012
Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemiaMarianne Hutchings Hoffmann, Tobias Wirenfeldt Klausen, Martin Boegsted, et al.
British Journal of Haematology|May 20, 2016
Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOPTina M Green, Andreas K Jensen, René Holst, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Briefings in Bioinformatics|April 23, 2013
Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/BioconductorMaria Rodrigo-Domingo, Rasmus Waagepetersen, Julie Støve Bødker, et al.
BMC Bioinformatics|April 13, 2016
Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive ratesAnders E Bilgrau, Steffen Falgreen, Anders Petersen, et al.
Plos One|May 12, 2011
Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell linesMartin Boegsted, Johanne M Holst, Kirsten Fogd, et al.
BMC Bioinformatics|June 7, 2014
Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibitionSteffen Falgreen, Maria Bach Laursen, Julie Støve Bødker, et al.
Diabetes Care|May 12, 2019
Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 TrialBruce W Bode, Violeta Iotova, Margarita Kovarenko, et al.
Oncotarget|January 27, 2015
MicroRNAs in B-cells: from normal differentiation to treatment of malignanciesSara Correia Marques, Maria Bach Laursen, Julie Støve Bødker, et al.
Danish Medical Journal|March 3, 2016
Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic reviewMette Østergaard Poulsen, Laura Krogh Jørgensen, Suzette Sørensen, et al.
Experimental Hematology|July 30, 2014
Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myelomaMaria Bach Laursen, Steffen Falgreen, Julie Støve Bødker, et al.
Cytometry. Part B, Clinical Cytometry|February 14, 2012
Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemiaMarianne Hutchings Hoffmann, Tobias Wirenfeldt Klausen, Martin Boegsted, et al.
British Journal of Haematology|May 20, 2016
Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOPTina M Green, Andreas K Jensen, René Holst, et al.
Pageof 2